Sex Pill to Help Women's Desire Shows Promise
Sex drug that works on brain shows promise in women's libido.
Nov. 16, 2009— -- In what is being hailed by some as the female Viagra, a new drug that failed to make it to market as an antidepressant is showing some hope for low libido in women.
In a multi-nation study made public Monday, the drug flibanserin appeared to increase desire and sexual satisfaction in women by several measures by modulating serotonin and other neurotransmitters.
Unlike Viagra, which is used to treat male erectile dysfunction by increasing blood flow to the genitals, this drug acts on the woman's brain to enhance mood.
Lead researchers from University of Ottawa -- underwritten by Boehringer Ingelheim Pharmaceuticals -- say the drug is effective in treating a newly coined condition known as hypoactive sexual desire disorder (HSDD) or lack of libido.
"This is a landmark study, and I think it's going to make a great difference for the quality of life for women throughout the world," said Dr. Elaine Jolly, director of the Women's Health Center at Ottawa Hospital in Canada. "This is just the beginning."
The drug acts on the central nervous system, keeping serotonin, norepinephrine and dopamine "in balance," she told ABCNews.com.
The Phase III placebo-controlled studies on flibanserin also raise questions about whether HSDD is a legitimate medical condition or another pharmaceutical company invention to sell drugs.
HSDD was classified as a disorder by the American Psychiatric Association in 2002 and is characterized by low desire, accompanied by "anxiety, guilt and relationships issues," according to Jolly.
"The pharmaceutical industry has come up with Viagra to solve a major concern that men have had since the beginning of time," said June Reinisch, senior research fellow at The Kinsey Institute for Research in Sex, Gender and Reproduction.
"But until now, nobody has seemed that concerned about resolving what women might like."
Reinisch said while the study was "interesting," there were more questions about the data -- women surveyed were 18 to 50, a wide range, and from different countries.
There was also a very strong placebo effect among the women.
"We ladies are complicated, and this study is only looking at one thing," she said. "It may be a first step in something interesting, but to call it a female Viagra, we are getting way ahead of ourselves."
"Women are not interested in getting a hard on, they want to have desire and arousal," said Reinisch, who is also a consultant to New York's Museum of Sex.
The randomized, double-blind study on flibanserin was carried out in Canada's Women's Health Center of the Ottawa Hospital, as well as at University of Virginia, University of North Carolina Chapel Hill and Italy's University of Pavia.
Related Stories
ABC News Live